Aktienanalyse zu Intensity Therapeutics Inc (INTS)INTSIntensity Therapeutics Inc

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Intensity Therapeutics Inc is not a good buy right now due to its significant financial losses and negative momentum. The stock has a current price of $3.00, a 52-week low of $2.80, and has declined 70.52% year-to-date. Additionally, the RSI is at 28.195, indicating oversold conditions but also a lack of bullish momentum. The most pressing risk is the company's widening losses, with a reported net loss of $3 million for Q2 2026, which raises concerns about its financial sustainability and operational capacity.